Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Leleu

Showing results (81-90 of 372) with videos related to

Pageof 38
Sort By:
Frontiers in Oncology|May 22, 2020
The Role of Immunotherapy in Non-transplant Eligible Multiple MyelomaArthur Bobin, Hélène Gardeney, Florence Sabirou, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Haematologica|June 13, 2012
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaBertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, et al.
Hematological Oncology|February 16, 2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trialsMaria-Victoria Mateos, Hartmut Goldschmidt, Jesus San-Miguel, et al.
Blood Cancer Journal|March 13, 2021
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myelomaPaul G Richardson, Thierry Facon, William I Bensinger, et al.
European Journal of Haematology|December 18, 2008
Update on therapeutic options in Waldenström macroglobulinemiaXavier Leleu, Julie Gay, Aldo M Roccaro, et al.
Expert Opinion on Investigational Drugs|September 14, 2020
Melflufen for relapsed and refractory multiple myelomaAlbert Oriol, Alessandra Larocca, Xavier Leleu, et al.
American Journal of Hematology|June 18, 2011
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemiaRanjit Banwait, Kevin O'Regan, Federico Campigotto, et al.
Haematologica|April 8, 2017
Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibitionMérédis Favreau, Koen Venken, Sylvia Faict, et al.
British Journal of Haematology|March 14, 2019
Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cellsEmilie Cayssials, Florence Jacomet, Nathalie Piccirilli, et al.
Pageof 38

Showing results (81-90 of 372) with videos related to

Sort By:
Pageof 38
Frontiers in Oncology|May 22, 2020
The Role of Immunotherapy in Non-transplant Eligible Multiple MyelomaArthur Bobin, Hélène Gardeney, Florence Sabirou, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Haematologica|June 13, 2012
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaBertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, et al.
Hematological Oncology|February 16, 2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trialsMaria-Victoria Mateos, Hartmut Goldschmidt, Jesus San-Miguel, et al.
Blood Cancer Journal|March 13, 2021
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myelomaPaul G Richardson, Thierry Facon, William I Bensinger, et al.
European Journal of Haematology|December 18, 2008
Update on therapeutic options in Waldenström macroglobulinemiaXavier Leleu, Julie Gay, Aldo M Roccaro, et al.
Expert Opinion on Investigational Drugs|September 14, 2020
Melflufen for relapsed and refractory multiple myelomaAlbert Oriol, Alessandra Larocca, Xavier Leleu, et al.
American Journal of Hematology|June 18, 2011
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemiaRanjit Banwait, Kevin O'Regan, Federico Campigotto, et al.
Haematologica|April 8, 2017
Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibitionMérédis Favreau, Koen Venken, Sylvia Faict, et al.
British Journal of Haematology|March 14, 2019
Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cellsEmilie Cayssials, Florence Jacomet, Nathalie Piccirilli, et al.
Pageof 38